Evidence map›Paper›PMID 35815265›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Effects of Tenofovir Combined with Recombinant Human Interferon

Hui Zhang, Jianchun Xian, Yang Li, Li Xiao, Lu Wang

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Retracted: Effects of Tenofovir Combined with Recombinant Human InterferonEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hui ZhangThe Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou 225300, China.
Jianchun XianThe Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou 225300, China.
Yang LiThe Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou 225300, China.
Li XiaoThe Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou 225300, China.
Lu WangThe Medical Department of Neurology, Jiangsu Taizhou People's Hospital, Taizhou 225300, China.ORCID https://orcid.org/0000-0002-1266-7916
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To systematically evaluate the clinical value of tenofovir combined with recombinant human interferon Methods: The randomized controlled trials (RCTs) of tenofovir combined with recombinant human interferon Results: Entecavir combined with recombinant human interferon Conclusion: Tenofovir combined with recombinant human interferon alpha-2b has a high serum HBeAg negative rate and safety profile for the treatment of chronic hepatitis B. The combination treatment can improve liver function and immune status in patients, but more studies with higher methodological quality and longer duration of intervention are needed for further validation.

Identifiers

PMID35815265
PMCPMC9262527
OpenAlexW4283758388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.